retatrutide phase 2 trial results obesity Michael Weintraub, MD on X: "Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight Retatrutide Phase 2 Results: 24.2%
Pay in 4 interest-free payments of $7.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18


























